Revolution Medicines, Inc. Proceeds from issuance of common stock relating to employee stock plans increased by 194.5% to $12.21M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1270.3%, from $891.00K to $12.21M. Over 3 years (FY 2021 to FY 2024), Proceeds from issuance of common stock relating to employee stock plans shows an upward trend with a 102.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher proceeds generally correlate with higher employee participation in equity plans and can indicate positive sentiment regarding the company's long-term stock performance.
Cash inflows resulting from the exercise of employee stock options or purchases through employee stock purchase plans. T...
Standard for most publicly traded companies with equity-based compensation programs.
financing_proceeds_from_stock_plans| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $257.00K | $319.00K | $356.00K | $305.00K | $190.00K | $209.00K | $777.00K | $499.00K | $468.00K | $1.01M | $1.34M | $810.00K | $4.34M | $3.00M | $4.18M | $891.00K | $1.94M | $4.15M | $12.21M |
| QoQ Change | — | +24.1% | +11.6% | -14.3% | -37.7% | +10.0% | +271.8% | -35.8% | -6.2% | +116.0% | +32.3% | -39.5% | +435.8% | -30.9% | +39.3% | -78.7% | +117.4% | +114.0% | +194.5% |
| YoY Change | — | — | — | — | -26.1% | -34.5% | +118.3% | +63.6% | +146.3% | +383.7% | +72.2% | +62.3% | +827.4% | +196.8% | +212.3% | +10.0% | -55.4% | +38.1% | >999% |